News & Updates
Filter by Specialty:
Novel drug STRIDES in the right direction for knee OA
In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).
Novel drug STRIDES in the right direction for knee OA
21 Jun 2023
Add-on mRNA cancer vaccine delivers promise for melanoma
Adding mRNA-4157, an investigational personalized neoantigen cancer vaccine, to the immune checkpoint inhibitor (ICI) pembrolizumab significantly improved recurrence-free survival (RFS) in individuals with resected high-risk melanoma, findings from the phase IIb KEYNOTE 942 study suggest.
Add-on mRNA cancer vaccine delivers promise for melanoma
20 Jun 2023
Abatacept halts RA progression early in high-risk group
Treatment with abatacept for a year halts disease progression in high-risk patients presenting with signs of imminent onset of rheumatoid arthritis (RA) in the phase IIb APIPPRA trial.
Abatacept halts RA progression early in high-risk group
20 Jun 2023
Dual-target oral drug outperforms tofacitinib in RA treatment
The novel, highly selective dual JAK1/TYK2 inhibitor TLL-018 appears to have better efficacy than the currently approved JAK inhibitor tofacitinib in the treatment of patients with rheumatoid arthritis (RA), according to the results of a head-to-head trial presented at EULAR 2023.
